Description

Coenzyme Q0 (CoQ0) is a potent, oral active ubiquinone compound can be derived from Antrodia cinnamomea. Coenzyme Q0 induces apoptosis and autophagy, suppresses of HER-2/AKT/mTOR signaling to potentiate the apoptosis and autophagy mechanisms. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of inflammation and redox imbalance. Coenzyme Q0 has anti-angiogenic activity through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling[1][2][3].–20°C, 3 years; 4°C, 2 years (Powder)-Applications-COVID-19-anti-virus-Formula-C9H10O4-Citation–References-[1]Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.|[2]Yang HL, et, al. Coenzyme Q0 regulates NFκB/AP-1 activation and enhances Nrf2 stabilization in attenuation of LPS-induced inflammation and redox imbalance: Evidence from in vitro and in vivo studies. Biochim Biophys Acta. 2016 Feb;1859(2):246-61.|[3]Yang HL, et, al. Anti-angiogenic properties of coenzyme Q0 through downregulation of MMP-9/NF-κB and upregulation of HO-1 signaling in TNF-α-activated human endothelial cells. Biochem Pharmacol. 2015 Nov 1;98(1):144-56.-CASNumber-605-94-7-MolecularWeight-182.18-Compound Purity-99.88-SMILES-O=C1C(OC)=C(OC)C(C(C)=C1)=O-Research_Area-Cancer; Inflammation/Immunology; Neurological Disease-Solubility-DMSO : 50 mg/mL (ultrasonic)-Target-Akt;Apoptosis;Autophagy;Bcl-2 Family;Caspase;COX;EGFR;Interleukin Related;MMP;mTOR;NF-κB;NO Synthase;PARP;Reactive Oxygen Species;TNF Receptor-Isoform–Pathway-Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Immunology/Inflammation;JAK/STAT Signaling;Metabolic Enzyme/Protease;NF-κB;PI3K/Akt/mTOR;Protein Tyrosine Kinase/RTK-MCE Product type-Biochemical Assay Reagents